Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 5/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.31 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.31 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.31 |
| ▸ | PGR | P06401 | 1/20 | 0.31 |
| ▸ | ESRRA | P11474 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | PPARG | P37231 | 1/20 | 0.31 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.31 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7121854 | 0.91 | ESR1 (0.41) | ESR1ESR2NR1I2NR3C1PGR | |
| SCHEMBL7120288 | 0.91 | ESR1 (0.41) | ESR1ESR2NR1I2NR3C1PGR | |
| SCHEMBL7119245 | 0.91 | ESR1 (0.41) | ESR1ESR2NR1I2NR3C1PGR | |
| SCHEMBL6796356 | 0.91 | ESR1 (0.41) | ESR1ESR2NR1I2NR3C1PGR | |
| SCHEMBL7128675 | 0.91 | ESR1 (0.41) | ESR1ESR2NR1I2NR3C1PGR | |
| SCHEMBL7118594 | 0.91 | ESR1 (0.41) | ESR1ESR2NR1I2NR3C1PGR | |
| SCHEMBL7128081 | 0.91 | ESR1 (0.41) | ESR1ESR2NR1I2NR3C1PGR | |
| SCHEMBL7122216 | 0.91 | ESR1 (0.41) | ESR1ESR2NR1I2NR3C1PGR | |
| SCHEMBL7120337 | 0.91 | ESR1 (0.41) | ESR1ESR2NR1I2NR3C1PGR | |
| SCHEMBL7117923 | 0.91 | ESR1 (0.41) | ESR1ESR2NR1I2NR3C1PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6610733-B2 | Antiestrogen, therapeutic agent for breast cancer | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-08-26 | — | — | US | disclosed |
| US-20030125571-A1 | Optically active chroman and thiochroman derivatives | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-07-03 | — | — | US | disclosed |
| EP-1241165-A1 | OPTICALLY ACTIVE CHROMAN AND THIOCHROMAN DERIVATIVES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2002-09-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030125571-A1 | Optically active chroman and thiochroman derivatives | NR5A1, CYP19A1, SHBG | ESR1 8/4885ESR2 5/4885NR1I2 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.